1. Kirby A, Suchy M, Graf D, Calvert, ND, Charlton TA, Ben RN, Addison CL, Shuhendler A. 2024. It’s a trap! Aldolase-prescribed C4-deoxyfluorination affords intracellular trapping and the tracing of fructose metabolism by PET. J Nucl Med. 2024 Mar 1;65(3):475-480. doi: 10.2967/jnumed.123.266905

2. Zhao H, Pond G, Simos D, Wang Z, Robertson S, Singh G, Vandermeer L, Clemons M, Addison CL. 2023. Doxycycline-induced changes in circulating MMP or TIMP2 levels are not associated with skeletal-related event- free or overall survival in bone metastatic breast cancer patients. Cancers: Special issue “Invasion and Progression of Solid Tumors in Bone”. 15, 571. doi.org/10.3390/cancers15030571

3. *Allen V, Coulombe J, Zhao H, *Kreps LM, Cook DP, Pryce B, Clemons M, Vanderhyden BC, Gray DA, Addison CL. 2022. VIVA1: a more invasive subclone of MDA-MD-134VI invasive carcinoma cells with increased metastatic potential in xenograft models. Br J Cancer. 2022 Jul;127(1):56-68. doi:10.1038/s1416-022-01778-7. Epub 2022 Mar 22. PMID 35318435

4. *Gunn SA, *Kreps LM, Zhao H, Landon K, *Ilacqua JS, Addison CL. 2022. Focal adhesion kinase inhibitors prevent osteoblast mineralization in part due to suppression of Akt-mediated stabilization of osterix. J Bone Oncol. 2022 May 13;34”100432. Doi: 10.1016/j.jbo.2022.100432.ecollection 2022 Jun. PMID:35620245
 
5. Beltran-Bless AA, Murshed M, Zakikhani M, Kuchuk I, Bouganim N, Robertson S, Kekre N, Vandermeer L, Li J, Addison CL, Rauch F, Clemons M, Kremer R. 2021. Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients. Bone Rep. 2021 Oct 22;15:101145. doi: 10.1016/j.bonr.2021.101145. eCollection 2021 Dec.

6. Brun E, Calvert N, Suchý M, Kirby A, Melkus G, Garipov R, Addison CL, Shuhendler A. 2021. Mapping Vitamin B6 Metabolism by HydrazoCEST Magnetic Resonance Imaging. Chemical Communications (Camb).;Oct 19;57(83):10867-10870. doi: 10.1039/d1cc03704h

7. *Kreps L, Addison CL. 2021. Targeting intercellular communication in the bone microenvironment to prevent disseminated tumor cell escape from dormancy and bone metastatic tumor growth. Int J of Mol Sci. Mar 13;22(6):2911. doi: 10.3390/ijms22062911.

8. Sulaiman A, McGarry S, Chambers J, Al-Kadi E, Phan A, Li L, Mediratta K, Dimitroulakos J, Addison C, Li X, Wang L. 2020. Targeting hypoxia sensitizes TNBC to cisplatin and promotes inhibition of both bulk and cancer stem cells. Int J Mol Sci. Aug 12;21(16):5788. Doi 10.3390/ijms21165788.

9. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen C, Diamandis EP, Siu KWM, Marshall JG. 2019. The plasma peptides of breast versus ovarian cancer. Clin Proteomics. Dec 23;16:43. doi: 10.1186/s12014-019-9262-0. eCollection 2019. 

10. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen CE, Diamandis EP, Michael Siu KW, Marshall JG. 2018. The plasma peptides of ovarian cancer. Clin Proteomics. Dec 21;15:41. doi: 10.1186/s12014-018-9215-z. eCollection 2018.

All Other Publications

1. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen C, Diamandis EP, Siu KWM, Marshall JG. 2018. The plasma peptidome. Clin Proteomics. 2018 Dec 1;15:39. doi: 10.1186/s12014-018-9211-3. eCollection 2018.

2. Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, Li L, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Liu S, Xie Y, Gadde S, Li X, Wang L. 2018. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018 Jul 26;9(8):815. doi: 10.1038/s41419-018-0811-7.

3. Sulaiman A, McGarry S, Li L, Jia D, Ooi S, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Gadde S, Li X, Wang L. 2018. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Mol Oncol. 2018 Apr;12(4):423-440. doi: 10.1002/1878-0261.12167. Epub 2018 Feb 21.

4. Hilton, J, Clemons, M, Pond, G, Zhao, H, Mazzarello, S, Vandermeer, L, Addison, CL. 2017. Effects on Bone Resorption Markers of Continuing Pamidronate or Switching to Zoledronic Acid in Patients with High Risk Bone Metastases from Breast Cancer. Journal of Bone Oncology, Nov 8;10:6-13. doi: 10.1016/j.jbo.2017.11.001

5. Howe GA, Kazda K, Addison CL. 2017. MicroRNA-30b controls endothelial cell capillary morphogenesis through regulation of transforming growth factor beta 2. PLoS One. 2017 Oct 4;12(10):e0185619. doi: 10.1371/journal.pone.0185619. eCollection 2017.

6. Laurie, SA, Hao, D, Leighl, NB, Goffin, J, Khomani, A, Gupta, A, Addison, CL, Bane, A, Seely, J, Filion, ML, Pond, GR, Levine, MN. 2017. A Phase II Trial of Dovitinib in Previously-Treated Advanced Pleural Mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer, 104:65-69.

For more publications use this PubMed ID link.